Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLS-S3
- Development stage
- Preclinical
- Lead developer
- Cellus
- Modality
- Small Molecules
01
Overview
CLS-S3 is a preclinical-stage small molecule inhibitor of cyclin-dependent kinase 7 (CDK7) being developed by Cellus for the treatment of Myc-driven tumors, including triple-negative breast cancer (TNBC). By inhibiting CDK7, CLS-S3 suppresses the expression of the MYC proto-oncogene at the transcriptional level, effectively regulating MYC expression and promoting apoptosis in cancer cells. In preclinical animal models of TNBC, CLS-S3 has demonstrated significant antitumor efficacy.
02
Targets
CDK7
Beyond the preview
Go deeper on CLS-S3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLS-S3.